Study Title
LASER - a Phase 2 Trial of 177Lu-PSMA-617 as Systemic Therapy for Renal Cell Carcinoma
Study Details
Description:
This study aims to evaluate the efficacy and safety of 177Lu-PSMA-617 as a systemic therapy in patients with PSMA-positive advanced clear cell renal cell carcinoma (ccRCC).
Sponsor:
Dana-Farber Cancer Institute
Contacts:
Praful Ravi, MB BCHir, MRCPpraful_ravi@dfci.harvard.edu
617-632-3466
Government Study Link:
NCT06964958 - Click here to see study onClinicalTrials.gov
Drug Details
177Lu-PSMA-617
Isotope(s):
- LUTETIUM-177
LUTETIUM-177
Radioisotope: Lu-177
Theranostic Role: Therapeutic Agent & SPECT Imaging
T1/2 (Half-Life): 6.7 Days
Decay Mode: BETA, GAMMA
Energy: Eβeta max 497 keV, Gamma 113-208 keV
Range: In Tissue: 0.25-2mm
Decay Daughters: Hf177
Status: FDA Approvals: PLUVICTO® (2022), LUTATHERA® (2017)
Target(s):
- PSMA
Ligand: Small Molecules
Chelator: DOTA
